A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)
NCT07049887 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2026-04-30
Summary
This study will collect information from patients with Primary Biliary Cholangitis (PBC).
PBC is a progressive rare liver disease in which tubes in the liver called bile ducts are damaged. The liver damage in PBC may lead to scarring (cirrhosis). People living with PBC often face challenges like intense itching, trouble sleeping, and feeling constantly tired. These symptoms can make it hard for them to enjoy daily life and feel well overall.
While itching and sleep patterns can be difficult to measure accurately based on recall and may lack precision, the main aim of this study is to use a digital health tool to assess the severity of itchiness and sleep patterns in people with PBC. The tool will take the objective measurement for people so they do not have to recall their scratch and sleep patterns. The total study duration for each patient will be about 91 days.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ipsen Medical Director · Ipsen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-16
- Primary Completion
- 2026-02-23
- Completion
- 2026-02-23
Countries
- United States
Study Locations
More Related Trials
-
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
NCT07304843 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Pentoxifylline for Primary Biliary Cirrhosis
NCT01249092 ·Status: COMPLETED ·Phase: PHASE2
-
Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis
NCT00393185 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136 ·Status: RECRUITING ·Phase: PHASE2
-
Monitoring the Response of Combination Ursodiol and Seladelpar Treatment
NCT07122206 ·Status: NOT_YET_RECRUITING
-
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
NCT05014672 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
NCT04526665 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
NCT03394924 ·Status: COMPLETED ·Phase: PHASE2
-
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
NCT02955602 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
NCT03742973 ·Status: TERMINATED ·Phase: PHASE2
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
NCT05201404 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
NCT05525520 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
NCT07325526 ·Status: RECRUITING ·Phase: PHASE2
-
Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis
NCT02061540 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
NCT06383403 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)
NCT04956328 ·Status: UNKNOWN ·Phase: PHASE3
-
ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
NCT03602560 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)
NCT02609048 ·Status: TERMINATED ·Phase: PHASE2
-
IBAT Inhibitor A4250 for Cholestatic Pruritus
NCT02360852 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
NCT05627362 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis
NCT00004842 ·Status: COMPLETED ·Phase: PHASE1
-
Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
NCT05292872 ·Status: COMPLETED
-
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
NCT04620733 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
NCT06730061 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3